At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Avantect Pancreatic Cancer Test (device)
- How long the study runs
- Study runs about 86 months (dates as stated)
- About the drug or intervention
- Avantect Pancreatic Cancer Test — device: Avantect test
- Patient visit burden
- "Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit." (as stated by sponsor)
- Type of study
- Testing a treatment
- Ages
- 50 Years to 84 Years
- Who
- All
- Number of participants
- 5,000
- Started
- 2025-05-21
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for diabetes mellitus
- • NA - 5,000 participants
- • The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days
Who can take part?
- • Ages 50 Years to 84 Years
- • Diagnosed with diabetes mellitus
Where?
- • Sandbach - Ashfields Primary Care Centre
- • Maidstone - Maidstone and Tunbridge Wells NHS Trust
- • Leicester - Forest Medical Group
- • Kibworth Beauchamp - South Leicestershire Medical Group
- • +27 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
More detail
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival. There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage. People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing. The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years. Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 50 Years - 84 Years
- Who can join: All genders
What the study is looking for
- ✓50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- ✓Willing to provide up to 30 mL of blood for each study visit
- ✓Willing and eligible to undergo MRI or CT scan
- ✓Understands the study process and is willing to take part in the study and sign the agreement to take part form
Who cannot take part
- ✗Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day...
- ✗A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- ✗Under investigation for or confirmed pancreatic cancer
- ✗Under investigation/surveillance for pancreatic cyst
- ✗Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
See the full criteria
Where Is This Study? (31 UK sites)
Ashfields Primary Care Centre
Sandbach CW11 1EQ, United Kingdom
Maidstone and Tunbridge Wells NHS Trust
Maidstone ME16 9QQ, United Kingdom
Forest Medical Group
Leicester LE3 3LW, United Kingdom
South Leicestershire Medical Group
Kibworth Beauchamp LE8 0LG, United Kingdom
Peel Croft Surgery
Burton-on-Trent DE14 3RH, United Kingdom
Kingswinford Medical Practice
Kingswinford DY6 8DN, United Kingdom
Park Medical Centre
Leek ST13 6QR, United Kingdom
Trinity Court Surgery
Stratford-upon-Avon CV37 6HJ, United Kingdom
Brockwood Medical Practice
Brockham RH3 7NJ, United Kingdom
Integrated Care Partnership/ The Old Cottage Hospital
Epsom KT17 4BL, United Kingdom
Warlingham Green Medical Practice
Warlingham CR6 9NW, United Kingdom
Ashton Medical Group
Ashton-under-Lyne OL6 6HD, United Kingdom
Yardley Wood Health Centre
Birmingham B14 4DU, United Kingdom
Bournemouth Research Hub
Bournemouth BH7 7DW, United Kingdom
Research Development & Support
clinicalresearch@bournemouth.ac.uk01202 961200Eastham Group Practice
Bromborough CH62 6EE, United Kingdom
Willesden Medical Centre
London NW10 2PT, United Kingdom
South Westminster Centre
London SW1P 2PF, United Kingdom
The Cuckoo Lane Practice
London W7 1DR, United Kingdom
Bodey Medical Centre
Manchester M14 6WP, United Kingdom
Bowland Medical Practice
Manchester M23 1JX, United Kingdom
The Maples Medical Centre
Manchester M23 2SY, United Kingdom
King's Mill Hospital (Sherwood Forest) Research Van
Nottingham NG17 4JL, United Kingdom
Portsmouth Research Hub
Portsmouth PO1 3HN, United Kingdom
Hazelvalley Family Practice
Rossendale BB4 5SL, United Kingdom
Pembroke Centre (Hillingdon)
Ruislip HA4 8NX, United Kingdom
Southampton Research Hub (Shirley Research Hub)
Southampton SO15 33UA, United Kingdom
Moorgreen Hospital
Southampton SO30 3JB, United Kingdom
Balance Street Health Centre
Uttoxeter ST14 8JG, United Kingdom
Civic Centre
Uxbridge UB8 1UW, United Kingdom
Quinton Practice
Walsall WS6 6EW, United Kingdom
Weymouth Research Hub
Weymouth DT4 0QE, United Kingdom
How to Get in Touch
SAFE-D Trial Manager
Sponsor contactCONTACT